Israeli fertility startup AIVF introduced Tuesday it had acquired ART Compass, an organization that makes lab administration software program for in vitro fertilization.
AIVF’s fundamental product is the EMA platform, which it says makes use of synthetic intelligence to evaluate embryo high quality throughout IVF remedy. The corporate mentioned the deal will add to its providing and assist it construct momentum within the U.S. market.
ART Compass’ founder Carol Lynn Curchoe will be part of AIVF as director of medical affairs. The corporate plans to combine the newly acquired software program into the EMA platform within the first quarter subsequent 12 months.
“This primary acquisition provides novel capabilities for the enlargement and integration of our FertilityOS in clinics,” mentioned AIVF CEO and cofounder Daniella Gilboa, , mentioned in an announcement. “Strategic business partnerships like this help our mission to speed up the digital transformation of fertility care.”
THE LARGER TREND
Based in 2018, AIVF received a European CE mark for its EMA platform final 12 months. It lately scooped up $25 million in Series A funding, which the corporate plans to make use of to broaden adoption of its expertise within the U.S. and Europe.
There are a variety of well being tech startups tackling fertility as extra companies offer benefits for fertility care like IVF.
One other firm touting AI-assisted IVF expertise is Alife Well being, which this week launched its platform that goals to assist clinics make selections through the IVF course of and streamline workflow. The corporate introduced a $22 million raise in March and a $9.5 million seed in Could 2021.
Kindbody has additionally been increasing its fertility companies. Earlier this 12 months, Kindbody purchased Vios Fertility Institute, a community of fertility clinics. It is also added in-house genetic testing and surrogacy services by way of acquisitions in 2022.
